Edition:
United States

Aeglea Bio Therapeutics Inc (AGLE.OQ)

AGLE.OQ on NASDAQ Stock Exchange Global Market

6.45USD
2:37pm EST
Change (% chg)

$0.13 (+2.06%)
Prev Close
$6.32
Open
$6.32
Day's High
$6.49
Day's Low
$6.32
Volume
20,816
Avg. Vol
14,765
52-wk High
$8.14
52-wk Low
$2.81

Latest Key Developments (Source: Significant Developments)

Aeglea Biotherapeutics announces clinical collaboration with Merck
Monday, 16 Oct 2017 08:00am EDT 

Oct 16 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer.Aeglea Bio Therapeutics Inc - ‍collaboration agreement is between Aeglea Biotherapeutics and Merck, through a subsidiary​.Aeglea Bio Therapeutics Inc - ‍additional details of collaboration were not disclosed​.Aeglea Bio Therapeutics Inc - ‍enrollment to multicenter phase 1/2 study​ is expected to begin in Q1 of 2018.  Full Article

Aeglea Bio Therapeutics doses 2 patients in repeat dose as part of clinical trial
Wednesday, 6 Sep 2017 07:00am EDT 

Sept 6 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Bio Therapeutics doses two patients in repeat dose part of phase 1/2 clinical trial for the treatment of arginase 1 deficiency.Aeglea Bio Therapeutics -‍dosed 2 adults in repeat dose part of phase 1/2 clinical trial of AEB1102 for treatment of patients with Arginase 1 Deficiency​.  Full Article

Aeglea BioTherapeutics reports Q2 loss per share $0.47‍​
Wednesday, 9 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Aeglea BioTherapeutics Inc -:Aeglea BioTherapeutics provides corporate update and reports second quarter 2017 financial results.Q2 revenue $1.5 million versus I/B/E/S view $1.3 million.Aeglea BioTherapeutics - qtrly loss per share $0.47‍​.  Full Article

Aeglea Bio Therapeutics Inc's says CEO resigned
Thursday, 20 Jul 2017 04:01pm EDT 

July 20 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Bio Therapeutics Inc - ‍announced that David G. Lowe, PH.D., resigned as company's president, chief executive officer​.Aeglea Bio Therapeutics Inc - Anthony Quinn, M.B CH.B, PH.D., has been appointed to serve as interim chief executive officer​.Aeglea Bio Therapeutics Inc - conducting search for a permanent chief executive officer​.  Full Article

Aeglea Biotherapeutics says public offering of 3 mln shares priced at $4.10 per share
Tuesday, 6 Jun 2017 09:20am EDT 

June 6 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Biotherapeutics prices public offering of common stock.Aeglea Bio Therapeutics - pricing of its underwritten public offering of 3 million shares of common stock at a public offering price of $4.10 per share.  Full Article

Aeglea Biotherapeutics announces proposed public offering of common stock
Monday, 5 Jun 2017 04:01pm EDT 

June 5 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Biotherapeutics announces proposed public offering of common stock.‍Aeglea intends to use net proceeds from offering to fund research and development of its product candidates among others​.  Full Article

Aeglea Biotherapeutics Q1 revenue $1.0 mln vs $900,000
Tuesday, 9 May 2017 08:00am EDT 

May 9 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea biotherapeutics provides corporate update and reports first quarter 2017 financial results.Q1 revenue $1.0 million versus $900,000.Q1 revenue view $1.7 million -- Thomson Reuters I/B/E/S.Aeglea bio therapeutics inc - net loss totaled $6.2 million and $4.5 million for q1 of 2017 and 2016, respectively.Aeglea bio therapeutics inc - at march 31, 2017, aeglea had available cash, cash equivalents and marketable securities of $57.9 million.  Full Article

Aeglea Bio Therapeutics files for mixed shelf of up to $150 mln
Monday, 1 May 2017 04:00pm EDT 

May 1 (Reuters) - Aeglea Bio Therapeutics Inc :Files for mixed shelf of up to $150 million - SEC filing.  Full Article

Aeglea Bio Q4 revenue $1.2 million versus $1.6 million
Thursday, 23 Mar 2017 04:05pm EDT 

Aeglea Bio Therapeutics Inc : Aeglea biotherapeutics provides corporate update and reports fourth quarter and full year 2016 financial results . Q4 revenue $1.2 million versus $1.6 million . Q4 revenue view $3.4 million -- Thomson Reuters I/B/E/S . Aeglea bio therapeutics inc- believes that it has sufficient capital resources to fund anticipated operations through q1 of 2019 .Aeglea bio therapeutics inc- net loss totaled $5.5 million and $4.0 million for q4 of 2016 and 2015, respectively.  Full Article

Aeglea Biotherapeutics to present topline data from phase 1 trial of AEB1102
Thursday, 23 Mar 2017 08:00am EDT 

Aeglea Bio Therapeutics Inc : Aeglea Biotherapeutics to present topline data from phase 1 trial of AEB1102 for treatment of Arginase I deficiency at 2017 ACMG annual clinical genetics meeting . Treatment with AEB1102 well tolerated, no related adverse events or clinically significant abnormal laboratory results reported .Study showed that single, intermittent doses of AEB1102 resulted in reduction of arginine in blood to normal levels.  Full Article

BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck

* Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer